eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics, Inc. (EFTR) Revenue
Annual & quarterly revenue history · segment & region breakdown
EFTR · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthseFFECTOR Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.00B, a decrease of 100.00% year-over-year from $0.00B in FY2023.
Revenue trend
2023 – 2019 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2023-12-31 | $0.00B | -$0.00B | -100.00% |
| 2022-12-31 | $0.00B | +$0.00B | +148.46% |
| 2021-12-31 | $0.00B | -$0.04B | -96.60% |
| 2020-12-31 | $0.04B | +$0.04B | — |
| 2019-12-31 | $0.00B | — | — |
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income eFFECTOR Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
eFFECTOR Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from eFFECTOR Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
EFTR revenue · 4 questionsEFTR's trailing twelve-month (TTM) revenue is $0.00B. That is a decrease of 100.00% year-over-year from $0.00B in FY2023.
▸ Source: FMP · eFFECTOR Therapeutics, Inc. SEC filings · GAAP · eFFECTOR Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026